ArticleNature cancer2024
Co-targeting SOS1 enhances the antitumor effects of KRAS
Abstract read
In one paragraph
Article in Nature cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed.
- Emerging Therapeutic Strategies for Non-G12C KRAS Mutations in Colorectal Cancer: Focusing on G12D and G12V.Journal of gastrointestinal cancer · 2026Review
- KRAS in Colorectal Cancer: Tumorigenesis, Surgical Implications and Evolving Treatment Target.Current oncology (Toronto, Ont.) · 2026Review
- Disrupting KRAS-AGO2 interaction: a dual-pronged strategy to sensitize chemo-immunotherapy in KRAS-mutated colorectal cancer.Apoptosis : an international journal on programmed cell death · 2026Article
- PI3K Regulates Wild-type RAS Signaling to Confer Resistance to KRAS Inhibition.Cancer research · 2026Article
- The SOS1 Inhibitor BI 1701963 as Monotherapy or in Combination with Trametinib in Patients with KRAS Mutation-Positive Solid Tumors.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Article
- KRAS G12C-Targeted Therapy in Non-Small Cell Lung Cancer: From Resistant Salvage to Potential First-Line Backbone.International journal of molecular sciences · 2026Review
- Serum SOS1 as a prognostic biomarker and therapeutic target for progressive liver disease.iScience · 2026Article
- Combined Inhibition of HRAS and MEK Induces Tumor Regression and Restores Myogenic Differentiation in HRAS-Mutant Rhabdomyosarcoma.Cancer research · 2026Article
- The Farnesyl Transferase Inhibitor Darlifarnib (KO-2806) Resensitizes Relapsing Tumors to RAS Inhibition.Cancer research · 2026Article
- Combining cutting edge computational and experimental methods for targeting KRAS mutations in non-small cell lung cancer.Expert opinion on drug discovery · 2026Review
- Dual RAF inhibition outperforms RAF-MEK combinations for suppressing ERK signaling in KRAS mutant cells.NPJ systems biology and applications · 2026Article
- KRAS and MYC synergistic inhibition: a powerful strategy targeting KRAS-mutant cancers.Molecular cancer · 2026Review
- SOS1: tracking the evolving path from promising to actionable therapeutic target in RAS-dependent cancers.Molecular cancer · 2026Review
- Systematic and precise interventions for KRAS-mutant cancers.Experimental hematology & oncology · 2026Review
- CRISPR-Cas9 Screening Identifies Resistance Mechanisms to KRAS Inhibition in Pancreatic Cancer.Cancer research · 2026Article
- Structure of SHOC2-KRAS-PP1C complex reveals RAS isoform-specific determinants and insights into targeting complex assembly by RAS inhibitors.Nature communications · 2026Article
- Disrupting the KRAS-SOS1 protein-protein interaction: mechanistic rationale for pan-KRAS pathway suppression and combination therapy.Frontiers in chemistry · 2026Review
- Modeling response to the KRAS-G12C inhibitor AZD4625 in KRASBritish journal of cancer · 2026Article
- Unravelling Resistance: Integrating Metabolism, Epigenetics, Immunology, and Proteostasis in Strategies against Kirsten Rat Sarcoma Viral Oncogene Homolog-mutant Colorectal Cancer.International journal of biological sciences · 2026Review
- KRAS-targeted therapies in colorectal cancer: a systematic analysis of mutations, inhibitors, and clinical trials.NPJ precision oncology · 2025Article
Corrections and comments
- Update ofCombined KRAS2023
Authors and funding
38 authors.
Venu Thatikonda *Boehringer Ingelheim RCV, Vienna, Austria. vthatikonda@exscientia.co.uk.ORCID 0009-0005-3886-8475
Hengyu Lyu *Translational Research to Advance Therapeutics and Innovation in Oncology (TRACTION) Platform, Therapeutics Discovery Division, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0003-1093-9364
Sabine JuradoBoehringer Ingelheim RCV, Vienna, Austria.
Kaja KostyrkoBoehringer Ingelheim RCV, Vienna, Austria.ORCID 0000-0002-2842-4089
Christopher A BristowTranslational Research to Advance Therapeutics and Innovation in Oncology (TRACTION) Platform, Therapeutics Discovery Division, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Christoph AlbrechtBoehringer Ingelheim RCV, Vienna, Austria.
Donat AlparBoehringer Ingelheim RCV, Vienna, Austria.ORCID 0000-0002-2638-5418
Heribert ArnhofBoehringer Ingelheim RCV, Vienna, Austria.
Oliver BergnerBoehringer Ingelheim RCV, Vienna, Austria.
Karin BoschBoehringer Ingelheim RCV, Vienna, Austria.
Ningping FengTranslational Research to Advance Therapeutics and Innovation in Oncology (TRACTION) Platform, Therapeutics Discovery Division, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Sisi GaoTranslational Research to Advance Therapeutics and Innovation in Oncology (TRACTION) Platform, Therapeutics Discovery Division, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Daniel GerlachBoehringer Ingelheim RCV, Vienna, Austria.ORCID 0000-0001-9338-3765
Michael GmachlBoehringer Ingelheim RCV, Vienna, Austria.
Melanie HinkelBoehringer Ingelheim RCV, Vienna, Austria.ORCID 0000-0002-0966-8045
Simone LiebBoehringer Ingelheim RCV, Vienna, Austria.
Astrid JeschkoBoehringer Ingelheim RCV, Vienna, Austria.
Annette A MachadoTranslational Research to Advance Therapeutics and Innovation in Oncology (TRACTION) Platform, Therapeutics Discovery Division, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Thomas MadenskyBoehringer Ingelheim RCV, Vienna, Austria.
Ethan D MarszalekTranslational Research to Advance Therapeutics and Innovation in Oncology (TRACTION) Platform, Therapeutics Discovery Division, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Mikhila MahendraTranslational Research to Advance Therapeutics and Innovation in Oncology (TRACTION) Platform, Therapeutics Discovery Division, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Gabriella Melo-ZainzingerBoehringer Ingelheim RCV, Vienna, Austria.
Jessica M MolkentineTranslational Research to Advance Therapeutics and Innovation in Oncology (TRACTION) Platform, Therapeutics Discovery Division, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0002-3757-7167
Philipp A JaegerBoehringer Ingelheim RCV, Vienna, Austria.
David H PengTranslational Research to Advance Therapeutics and Innovation in Oncology (TRACTION) Platform, Therapeutics Discovery Division, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Robyn L SchenkBoehringer Ingelheim RCV, Vienna, Austria.
Alexey SorokinDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Sandra StraussBoehringer Ingelheim RCV, Vienna, Austria.
Francesca TrapaniBoehringer Ingelheim RCV, Vienna, Austria.
Scott KopetzDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0001-9647-3416
Christopher P VellanoTranslational Research to Advance Therapeutics and Innovation in Oncology (TRACTION) Platform, Therapeutics Discovery Division, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Mark PetronczkiBoehringer Ingelheim RCV, Vienna, Austria.
Norbert KrautBoehringer Ingelheim RCV, Vienna, Austria.ORCID 0000-0003-3941-7105
Timothy P HeffernanTranslational Research to Advance Therapeutics and Innovation in Oncology (TRACTION) Platform, Therapeutics Discovery Division, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0002-3166-8922
Joseph R MarszalekTranslational Research to Advance Therapeutics and Innovation in Oncology (TRACTION) Platform, Therapeutics Discovery Division, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0003-2320-3209
Mark PearsonBoehringer Ingelheim RCV, Vienna, Austria.
Irene C WaizeneggerBoehringer Ingelheim RCV, Vienna, Austria.
Marco H HofmannBoehringer Ingelheim RCV, Vienna, Austria. marco.hofmann@boehringer-ingelheim.com.ORCID 0000-0001-7557-1156
Funding
Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8MProject 3: Inhibiting Oxidative Phosphorylation in Pancreatic CancerP50CA221707 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI KOPETZ, SCOTT, MAITRA, ANIRBAN · 2019 to 2023
$11.0MOvercoming adaptive feedback resistance to KRAS inhibition in colorectal cancerR01CA262805 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI Ryan Bruce Corcoran, Scott Kopetz · 2022 to 2026
$3.5MNCI NIH HHS P30 CA016672NCI NIH HHS P50 CA221707NCI NIH HHS R01 CA262805Österreichische Forschungsförderungsgesellschaft (Austrian Research Promotion Agency) 861507Österreichische Forschungsförderungsgesellschaft (Austrian Research Promotion Agency) 867897Österreichische Forschungsförderungsgesellschaft (Austrian Research Promotion Agency) 874517Österreichische Forschungsförderungsgesellschaft (Austrian Research Promotion Agency) 883626Österreichische Forschungsförderungsgesellschaft (Austrian Research Promotion Agency) 892584
Abstract
Combination approaches are needed to strengthen and extend the clinical response to KRAS
Indexed as
Drug Resistance, NeoplasmProto-Oncogene Proteins p21(ras)SOS1 ProteinAcetonitrilesAnimalsAntineoplastic Combined Chemotherapy ProtocolsCell Line, TumorColorectal NeoplasmsFemaleHumansLung NeoplasmsMiceMutationPiperazinesProtein Tyrosine Phosphatase, Non-Receptor Type 11PyrimidinesAcetonitrilesadagrasibKRAS protein, humanPiperazinesProtein Tyrosine Phosphatase, Non-Receptor Type 11Proto-Oncogene Proteins p21(ras)PyrimidinesSOS1 ProteinSOS1 protein, human
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.